Press

Insights

Contact Us

iPlato, a Huma company – home
News

/

A Year to Remember: Reflecting on 2024 at iPLATO

Macmillan Cancer Support announces winner of the Macmillan Innovation Challenge 2023/24

July 8, 2024

A Year to Remember: Reflecting on 2024 at iPLATO

By Tobias Alpsten, CEO and Founder of iPLATO 

As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.

The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.

What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.

This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.

Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.

We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.

We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.

Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.

We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.

Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together! 

Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.

This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.

In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.

Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.

iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.

With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.

Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.

As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health. 

Here’s to 2025!

Tobias

Press

Insights

Contact Us

iPlato, a Huma company – home

Practice Area

News

/

A Year to Remember: Reflecting on 2024 at iPLATO

Macmillan Cancer Support announces winner of the Macmillan Innovation Challenge 2023/24

July 8, 2024

A Year to Remember: Reflecting on 2024 at iPLATO

By Tobias Alpsten, CEO and Founder of iPLATO 

As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.

The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.

What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.

This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.

Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.

We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.

We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.

Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.

We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.

Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together! 

Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.

This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.

In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.

Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.

iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.

With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.

Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.

As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health. 

Here’s to 2025!

Tobias

Press

Insights

Contact Us

News

/

Macmillan Cancer Support announces winner of the Macmillan Innovation Challenge 2023/24

Macmillan Cancer Support announces winner of the Macmillan Innovation Challenge 2023/24

July 8, 2024

Today, leading cancer charity Macmillan Cancer Support announces HUMA as the winner of a £75,000 investment to further develop its systemic anti-cancer therapy Digital Checklist app, aimed to help improve the experience of cancer patients across the UK.

HUMA’s SACT (systemic anti-cancer therapy [1]) digital checklist allows patients to share health information via a mobile app which in turn allows clinicians to monitor their health remotely.

The app enables patients to answer a digital pre-screening checklist and share information such as vital signs and symptoms with clinicians from the comfort of their home. Clinicians can then review patient checklist answers and health data remotely to understand if they are ready to receive SACT and what they may need for their recovery. Currently, when cancer patients are pre-screened to check their health before receiving SACT, this is usually done over the telephone or in a physical appointment. This can be inconvenient for some patients and can add to the workload for clinicians.

The innovation from HUMA is designed to increase clinical capacity for the delivery of treatment, improve the patient experience and reduce stress for cancer patients. Virtual care has the potential to deliver a quality healthcare service for cancer patients, with the aim of making their experience more convenient, more streamlined, and more closely aligned to their needs. During the COVID-19 pandemic, the adoption of virtual wards and care, as well as remote monitoring, was accelerated. Early evidence suggests feedback from patients and staff has been positive. [2,3]

HUMA SACT was one of six innovations shortlisted for the Macmillan Innovation Challenge, delivered in partnership with three Health Innovation Networks: Health Innovation East, Health Innovation Kent Surrey Sussex and Health Innovation Yorkshire & Humber. The investment is one of several made as part of Macmillan’s investment portfolio which will invest £3.5 million over the next two years in startup businesses developing ground-breaking cancer care products and technology.

The HUMA SACT Digital Checklist was co-developed with clinicians from East Suffolk and North Essex NHS Foundation Trust at the Woolverstone Macmillan Centre. The checklist was implemented at the Woolverstone Centre in 2023 and initial feedback suggests it is helping improve patient experience and enhance clinical capacity. In partnership with Macmillan and the three Health Macmillan Public Innovation Networks, HUMA will now scale the deployment of the technology to increase reach and impact for people with cancer across the UK.

Health Innovation East, Health Innovation Kent Surrey Sussex and Health Innovation Yorkshire & Humber will facilitate introductions within the NHS and provide expertise to deliver a service evaluation gathering real-world evidence.

Anthony Cunliffe, National Lead Medical Adviser at Macmillan Cancer Support says “We’re delighted to announce HUMA as the winner of the Macmillan Health Innovation Challenge 2023. By using pioneering technology, HUMA’s SACT Digital Checklist app could have a transformational effect on cancer care across the UK by increasing clinical capacity and ultimately improving the experience for many cancer patients, by supporting them to have their health monitored in the comfort of their own home. This could reduce the need for them to travel to and from hospital, thus minimising their risk of infection.”

Karanjit Aujla, VP, Partnerships (HUMA): “We are thrilled that HUMA has won the Macmillan Innovation Challenge and are excited to collaborate with Macmillan to scale our digital SACT platform across the NHS. Our digital SACT checklist already shows a promise for increasing capacity and enhancing both patient and clinician experiences. SACT centers are under unsustainable pressure, and we hope that our solution can help the NHS manage the growing demand more effectively, by streamlining the assessment process and reducing unnecessary burdens on patients. Partnering with Macmillan presents an incredibly exciting opportunity, and together we will work towards improving the experience for many cancer patients and increasing SACT capacity at a critical time for the NHS.”

 

About Macmillan Cancer Support

At Macmillan, we give people with cancer everything we’ve got. If you’re diagnosed, your worries are our worries. We will do whatever it takes to help you live life as fully as you can. And we don’t stop there. We’re going all out to find ever better ways to help people with cancer, helping to bring forward the day when everyone gets life-transforming support from day one. As cancer is evolving, so must we. Macmillan will not settle for anything other than the best possible support for people living with cancer. As a charity, we can’t afford to stand still. Now more than ever, we need to take every chance to make a difference. But we cannot do it alone. We have been working with others for over 100 years and will continue to do so. So, we’re working to create a vision of Macmillan that is shaped side by side with the people and communities we exist to support.

To find out more about how Macmillan is doing this visit Transforming Macmillan together | Macmillan Cancer Support Macmillan Public

About the Macmillan Innovation Community

The Macmillan Innovation Community is an opportunity for people living with cancer to harness their knowledge and experience to shape innovative cancer care with Macmillan.

About HUMA

HUMA is a leading global digital health technology company that uses AI to advance digital-first care delivery and research to help people live longer, fuller lives. HUMA’s remote patient monitoring and virtual care service offers a flexible, digital-first approach to healthcare. The easy-to-use, configurable, platform-based digital solution manages patients across the care continuum. For more information, visit www.huma.com.

About The Health Innovation Network

The Health Innovation Network is the innovation arm of the NHS and the collective voice of 15 health innovation networks across England. The networks were created to spread innovation within the NHS, improve health and generate economic growth. The Health Innovation Network works with healthcare organisations and businesses to support the spread of all types of innovation within the NHS, from new technologies to ways of working and service improvements. Health innovation networks bring together the NHS, industry, academic, third sector and local organisations to ensure innovations, improvement and best practice benefit more patients faster. Visit https://thehealthinnovationnetwork.co.uk/for more information.

[1] Systemic anti-cancer therapy (SACT) is any drug treatment used to control or treat cancer, including chemotherapy and immunotherapy.

[2] NHS England. Virtual ward including Hospital at Home. March 2022. https://www.england.nhs.uk/wpcontent/uploads/2021/12/B1478-supporting-guidance-virtual-ward-including-hospital-at-home-march-2022-update.pdf (accessed April 2023)

[3] NHS England. A ‘Virtual Ward’ approach to supporting vulnerable and at-risk groups in the community. https://www.england.nhs.uk/nursingmidwifery/shared-governance-and-collective-leadership/nursingcovid-19-catalogue-of-change/a-virtual-ward-approach-to-supporting-vulnerable-and-at-risk-groups-inthe-community (accessed April 2023)